Canaccord Genuity Q2 Preview on Quest Diagnostics (NYSE: DGX): Sidelined Until More Confident in New CEO's Ability
Tweet Send to a Friend
Canaccord Genuity maintains a 'Hold' on Quest Diagnostics (NYSE: DGX) price target of $60.00.
Analyst, Jeffrey Frelick, said, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Jeffrey Frelick, said, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
